Cargando…
Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
BACKGROUND: A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery. However, the effectiveness and safety of neoadjuvant programmed cell death 1 (PD‐1) blockade combined with chemotherapy hav...
Autores principales: | Feng, Yuan, Sun, Wei, Zhang, Jie, Wang, Yang, Chen, Jinfeng, Liu, Xinying, Wang, Liang, Li, Shaolei, Lv, Chao, Lu, Fangliang, Zhang, Jianzhi, Hong, Yang, Xiao, Shanshan, Wang, Tao, Jiao, Raymond, Wang, Ziping, Qi, Liping, Li, Nan, Yang, Yue, Lin, Dongmei, Fang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807321/ https://www.ncbi.nlm.nih.gov/pubmed/34913597 http://dx.doi.org/10.1111/1759-7714.14280 |
Ejemplares similares
-
Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023) -
Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study
por: Huang, Zekai, et al.
Publicado: (2019) -
Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
por: Huang, Miao, et al.
Publicado: (2021) -
Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022) -
Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)